Enocitabine (INN, marketed under the brand name Sunrabin) is a nucleoside analog used as chemotherapy.

Enocitabine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
IV
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • N-[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]docosanamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC31H55N3O6
Molar mass565.796 g·mol−1
3D model (JSmol)
  • O=C(N/C/1=N/C(=O)N(\C=C\1)[C@@H]2O[C@@H]([C@@H](O)[C@@H]2O)CO)CCCCCCCCCCCCCCCCCCCCC
  • InChI=1S/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)/t25-,28-,29+,30-/m1/s1 checkY
  • Key:SAMRUMKYXPVKPA-VFKOLLTISA-N checkY

Sunrabin contains the emulsifier HCO-60, which can cause allergic reactions.[1]

References

edit
  1. ^ Tatetsu H, Asou N, Nakamura M, et al. (July 2003). "[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine]". Rinsho Ketsueki (in Japanese). 44 (7): 471–3. PMID 12931567.